May 02, 2022 / 10:45PM GMT
David Bailey - Macquarie Research - Analyst
Good morning, everyone. My name is David Bailey, I'm part of the healthcare team at Macquarie. Today's format will be a short introduction, followed by a Q&A session. If you do wish to submit a question, you can do so via the app. Moving on. It's my pleasure to introduce you to Brett Sandercock this morning, CFO of ResMed. Brett, perhaps we can start with some introductory comments in relation to your most recent results, and then we'll jump into Q&A from there.
Brett A. Sandercock - ResMed Inc. - CFO
Sure. Thanks, David. It's a real pleasure to join you this morning and hello, everyone. So what I thought I might do is just briefly recap on our Q3 results and just run through that with a few of the highlights there. So Q3 -- had a pretty solid performance in Q3. We had revenue growth of 14%. And of course, we were impacted by ongoing supply constraints and that definitely limited our ability to really supply and meet pretty unprecedented demand in the marketplace at the moment due to the Philips recall. So we
Resmed Inc at Macquarie Australia Conference Transcript
Jan 23, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers